← Back

Wire · operational-macro

FDA approves first ever plasmid DNA-based immunotherapy

Published

5 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 5 November 2026 · Fusion42 review

The FDA approved Voceryq, the first plasmid DNA-based immunotherapy, to treat recurrent respiratory papillomatosis caused by HPV, marking a breakthrough in DNA-based medicines. This approval validates plasmid DNA therapeutics as a treatment modality, expanding market potential beyond gene therapies and vaccines.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You can now build therapies using plasmid DNA as a proven regulatory path exists. Investors and partners will look for DNA-based platform innovators to replicate Inovio's breakthrough.

◆ Coverage

9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaldna-therapyhpv-treatmentbiotech-innovationimmunotherapy